Manufacturing mesenchymal stromal cells for phase I clinical trials.
Where this comes from
- Record sourced from PubMed, PMID 23480951.
- Also identified by DOI 10.1016/j.jcyt.2012.09.007 and PMC identifier 3611961.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mesenchymal stromal cells (MSCs) are multipotent progenitor cells capable of differentiating into adipocytes, osteoblasts and chondroblasts as well as secreting a vast array of soluble mediators. This potentially makes MSCs important mediators of a variety of therapeutic applications. They are actively under evaluation for immunomodulatory purposes such as graft-versus-host disease and Crohn's disease as well as regenerative applications such as stroke and congestive heart failure. We report our method of generating clinical-grade MSCs together with suggestions gathered from manufacturing experience in our Good Manufacturing Practices facility.
Medical subject headings
- Bone Marrow Cells
- Cell Culture Techniques
- Leukocytes, Mononuclear
- Mesenchymal Stem Cells